PharmEasy files for Rs 62.50 billion IPO
Bengaluru: Indian digital healthcare platform PharmEasy filed on Wednesday for an initial public offering (IPO) of up to 62.50 billion rupees ($842.43 million), becoming the latest startup in the country to pursue a domestic stock listing.
The company provides health services ranging from teleconsultation to radiology tests to home delivery of medical products and devices.
For the three months ended June 30, the proforma gross merchandise value or the total monetary value of all sales for the company stood at 30.26 billion rupees.
API Holdings Ltd, PharmEasy's parent, may also consider a further issue of equity shares via a private placement of up to 12.50 billion rupees, the company said in its draft red herring prospectus dated Nov. 8.
The company counts technology-focused venture capital firm Naspers and entities related to global investment group CDPQ and private-equity firm TPG among its investors.
In a bid to diversify its operations, the firm had acquired Thyrocare Technologies, India's largest diagnostic test provider by volumes, in September.
PharmEasy's IPO filing comes on a day when Indian fashion e-commerce startup Nykaa is set to debut on stock exchanges, while fintech platform Paytm closes subscription prior to its debut.
Citigroup Global Markets India, JM Financial Ltd, Kotak Mahindra Capital, Morgan Stanley India and BoFA Securities India are joint bookrunners in API Holdings' IPO.
Read also: PharmEasy parent appoints 5 independent directors
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.